|
Pharmapredict contains 3 key analyses - Launch Analysis, Success Analysis and Development Time Analysis. Our online demonstration provides an example of each, as well as illustrating the easy-to-use, online
functionality.
What can you learn from Launch Analysis?
The objective of Launch Analysis is to estimate when a drug or group of drugs
will reach the market, so you can identify future competitors or business opportunities.
To give you the full picture, for every drug you can analyse:
- Launch based on the developing company's track record
- Launch based on the therapeutic group the drug belongs to
- Launch based on the specific therapeutic classification of that drug
- Launch based on all drugs in Pharmapredict
You could, for example, either search for the predicted launch dates of all cancer
drugs. Or you could combine this with a phase of development and refine your search
to the launch dates of all cancer drugs that are in Phase III trials.
Example searches are given to illustrate the effect of combining search fields
and how easy it is to answer key questions. Search terms in red can be used on their own or in combination with one of the fields in blue.
|
|
Phase of development |
Predicted launch year |
Peak Sales (Evaluate data)* |
|
Therapy group |
Which cancer drugs are in Phase III trials and when will they reach the market?
|
Which neurological drugs will be launched between now and 2010? |
Which cardiovascular drugs have peak sales estimates above 500m US dollars and
when will they be launched? |
|
Specific therapy |
Which immunological cancer drugs are in late stage development and are due to
be launched in the next 3 years? |
Which Parkinson's treatments are due to reach the market over the next 10 years?
|
Which hypolipaemics have peak sales estimates above 500m US dollars and when
will they be launched? |
|
Company |
When will each of Genentech's late stage pipeline drugs reach the market? |
What will GSK launch in 2008-2010? |
What will Genentech launch in 2008-2012 with peak sales greater than 200m US
dollars? |
|
Pharmacology |
When will today's Phase II drugs acting on HER2 be launched? |
Which pipeline dopamine agonists will be launched within 5 years? |
Which PPAR agonists have peak sales potential of 200m US dollars? |
|
Drug name |
What is the predicted launch date of GlaxoSmithKline's mepolizumab? |
** Analyses based on primary therapy and pharmacology and originator company. | 
.gif)
